ABSTRACT
The monophasic combination preparation, Marvelon, is a modern, technically improved oral contraceptive. It was tested for contraceptive reliability, cycle control and acceptability in 4 clinical centers in Nigeria for a period of one year. A total of 408 women was included in these studies, and 3102 cycles were monitored. The results showed a high contraceptive reliability and an excellent cycle-control. It was well tolerated. There were very few side-effects and the symptoms during medication were minor and hardly needed any treatment. At 12 months, 43.1% of the acceptors were still in the trial. Seventy-nine women (19.4%) discontinued before the end of the study for any reason. Drop-out reasons of these women were mainly non-medical. For the remainder of drop-outs no reason was given. This study suggests that this new oral contraceptive adequately satisfies the contraceptive needs of modern women.
Subject(s)
Contraceptives, Oral/standards , Desogestrel/standards , Adolescent , Adult , Blood Pressure/drug effects , Blood Pressure/physiology , Body Weight/drug effects , Body Weight/physiology , Contraceptives, Oral/adverse effects , Contraceptives, Oral/pharmacology , Desogestrel/adverse effects , Desogestrel/pharmacology , Dose-Response Relationship, Drug , Female , Humans , Menstrual Cycle/drug effects , NigeriaABSTRACT
A multicenter study was conducted in Nigeria, comparing the Multiload-Cu250 (MLCu250) with the Multiload-Cu375 (MLCu375). The two intrauterine devices were studied on aspects of effectiveness and acceptability. Parameters were observed and analyzed, using the life-table method of Tietze and Lewit. Continuation rates were excellent. Overall results were in line with studies done elsewhere in the world with Multiload devices, showing a slight superiority of the MLCu375 over the MLCu250.
